These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 22949344)

  • 41. Eplerenone--a novel selective aldosterone blocker.
    Zillich AJ; Carter BL
    Ann Pharmacother; 2002 Oct; 36(10):1567-76. PubMed ID: 12243608
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New aldosteron receptor inhibitors in heart failure.
    Mandolini C; Vacca K; Borgia MC
    Minerva Cardioangiol; 2005 Aug; 53(4):241-8. PubMed ID: 16177669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Eplerenone after myocardial infarction?
    Drug Ther Bull; 2008 Jan; 46(1):1-3. PubMed ID: 18171726
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
    George J; Struthers AD
    Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Aldosterone antagonists for all patients with heart failure?].
    Bauersachs J
    MMW Fortschr Med; 2009 Apr; 151(15):33-5. PubMed ID: 19728679
    [No Abstract]   [Full Text] [Related]  

  • 46. Aldosterone target organ protection by eplerenone.
    Rudolph AE; Rocha R; McMahon EG
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):229-38. PubMed ID: 15134822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aldosterone blockade in patients with systolic left ventricular dysfunction.
    Pitt B
    Circulation; 2003 Oct; 108(15):1790-4. PubMed ID: 14557343
    [No Abstract]   [Full Text] [Related]  

  • 48. Pfizer launches Inspra for heart failure.
    Cardiovasc J S Afr; 2006; 17(4):220. PubMed ID: 17001435
    [No Abstract]   [Full Text] [Related]  

  • 49. [Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study].
    Watanabe J
    Nihon Rinsho; 2007 Apr; 65 Suppl 4():543-6. PubMed ID: 17508588
    [No Abstract]   [Full Text] [Related]  

  • 50. The clinical pharmacology of eplerenone.
    Muldowney JA; Schoenhard JA; Benge CD
    Expert Opin Drug Metab Toxicol; 2009 Apr; 5(4):425-32. PubMed ID: 19379127
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
    MMW Fortschr Med; 2003 Oct; 145(44):42-3. PubMed ID: 14655506
    [No Abstract]   [Full Text] [Related]  

  • 52. Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure.
    Talatinian A; Chow SL; Heywood JT
    Pharmacotherapy; 2012 Sep; 32(9):827-37. PubMed ID: 22949142
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evolving strategies for the use of spironolactone in cardiovascular disease.
    Jolobe OM
    Eur J Intern Med; 2013 Jun; 24(4):303-9. PubMed ID: 23245930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Preiss D; van Veldhuisen DJ; Sattar N; Krum H; Swedberg K; Shi H; Vincent J; Pocock SJ; Pitt B; Zannad F; McMurray JJ
    Eur J Heart Fail; 2012 Aug; 14(8):909-15. PubMed ID: 22611047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).
    Stier CT; Koenig S; Lee DY; Chawla M; Frishman WH
    Heart Dis; 2003; 5(2):102-18. PubMed ID: 12713678
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial.
    Collier TJ; Pocock SJ; McMurray JJ; Zannad F; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B
    Eur Heart J; 2013 Sep; 34(36):2823-9. PubMed ID: 23864130
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement].
    Kolloch R; Offers E
    MMW Fortschr Med; 2003 Nov; 145(47):42-4, 47. PubMed ID: 14725033
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The place of aldosterone receptor blockers in the treatment of chronic heart failure].
    Kardiologiia; 2005; 45(10):76-81. PubMed ID: 16234778
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
    Pitt B
    J Card Fail; 2002 Dec; 8(6 Suppl):S491-3. PubMed ID: 12555163
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF).
    Zannad F; McMurray JJ; Drexler H; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B
    Eur J Heart Fail; 2010 Jun; 12(6):617-22. PubMed ID: 20388647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.